Ocugen Past Earnings Performance
Past criteria checks 0/6
Ocugen's earnings have been declining at an average annual rate of -28.8%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 89.6% per year.
Key information
-28.8%
Earnings growth rate
66.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 89.6% |
| Return on equity | -155.5% |
| Net Margin | -1,045.0% |
| Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Ocugen announces peer-reviewed publication on COVID-19 vaccine
Sep 14Ocugen initiated with Buy at Mizuho citing favorable setup ahead of key readout
Aug 23Ocugen Q2 2022 Earnings Preview
Aug 04Ocugen: A First Take
Jul 18Ocugen in renewed focus as FDA wants COVID boosters to fight Omicron variant
Jul 05Where Will Ocugen Stock Be In 5 Years?
Apr 27Ocugen: FDA Lifts Clinical Hold As Shares Sink - It May Be Worth Staying The Course
Feb 24Ocugen: The Life After COVID-19
Jan 23Revenue & Expenses BreakdownBeta
How Ocugen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 6 | -63 | 32 | 0 |
| 30 Sep 23 | 0 | -76 | 34 | 0 |
| 30 Jun 23 | 0 | -83 | 33 | 0 |
| 31 Mar 23 | 0 | -80 | 33 | 0 |
| 31 Dec 22 | 2 | -87 | 35 | 0 |
| 30 Sep 22 | 0 | -74 | 36 | 0 |
| 30 Jun 22 | 0 | -63 | 32 | 0 |
| 31 Mar 22 | 0 | -69 | 29 | 0 |
| 31 Dec 21 | 0 | -58 | 23 | 0 |
| 30 Sep 21 | 0 | -48 | 18 | 0 |
| 30 Jun 21 | 0 | -47 | 15 | 0 |
| 31 Mar 21 | 0 | -38 | 10 | 0 |
| 31 Dec 20 | 0 | -34 | 8 | 0 |
| 30 Jun 20 | 0 | -30 | 8 | 1 |
| 31 Mar 20 | 0 | -18 | 7 | -3 |
| 31 Dec 19 | 0 | -20 | 6 | 0 |
| 30 Sep 19 | 0 | -39 | 6 | 9 |
| 30 Jun 19 | 0 | -18 | 6 | 4 |
| 31 Mar 19 | 0 | -19 | 6 | 11 |
| 31 Dec 18 | 0 | -18 | 6 | 10 |
Quality Earnings: OCGN is currently unprofitable.
Growing Profit Margin: OCGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OCGN is unprofitable, and losses have increased over the past 5 years at a rate of 28.8% per year.
Accelerating Growth: Unable to compare OCGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: OCGN has a negative Return on Equity (-155.5%), as it is currently unprofitable.